Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Cefotetan-Associated Coagulopathies

Cefotetan-Associated Coagulopathies Abstract To the Editor.—Two patients from our hospital (Hartford [Conn] Hospital) who developed coagulopathies supposedly from cefotetan were recently described in the Archives.1 Having had the opportunity to evaluate these cases in detail, and having a view different from that of the author (Dr Holt), we felt obliged to write this letter. While there was a temporal relationship between cefotetan therapy and the development of hypoprothrombinemias in these patients, there were a number of other reasons for the development of coagulopathies (ie, malignant neoplasm, poor nutritional status, concurrent use of agents that effect hemostasis, and renal or hepatic dysfunction). During cefotetan therapy the nutritional status of both patients deteriorated. The first patient was without oral intake for the initial six days of her eight-day course of treatment with cefotetan and received no enteral feedings or hyperalimentation during this period. The second patient was without oral intake for the majority References 1. Holt J: Hypoprothrombinemia and bleeding diathesis associated with cefotetan therapy in surgical patients . Arch Surg 1988;123:523.Crossref 2. Mann AJ: Cimetidine associated thrombocytopenia . Drug Intell Clin Pharm 1983;17:126-128. 3. Gafter U, Komlos L, Weinstein T, et al: Thrombocytopenia, eosinophilia, and ranitidine . Ann Intern Med 1987;106:477.Crossref 4. Gibson PR, Pidcock ME: Immune- mediated thrombocytopenia associated with ranitidine therapy . Med J Aust 1986;145:661-662. 5. Spychal RT, Wickham NW: Thrombocytopenia associated with ranitidine . Br Med J 1985;291:1687.Crossref 6. Dipyridamole package insert . Ridgefield, Conn, Boehringer Ingelheim Pharmaceuticals Inc, 1985. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Surgery American Medical Association

Cefotetan-Associated Coagulopathies

Download PDF
1 page

Cefotetan-Associated Coagulopathies

Abstract

Abstract To the Editor.—Two patients from our hospital (Hartford [Conn] Hospital) who developed coagulopathies supposedly from cefotetan were recently described in the Archives.1 Having had the opportunity to evaluate these cases in detail, and having a view different from that of the author (Dr Holt), we felt obliged to write this letter. While there was a temporal relationship between cefotetan therapy and the development of hypoprothrombinemias in these patients, there were a number...
Loading next page...
 
/lp/american-medical-association/cefotetan-associated-coagulopathies-80MjX9Dji0

References (9)

Publisher
American Medical Association
Copyright
Copyright © 1989 American Medical Association. All Rights Reserved.
ISSN
0004-0010
eISSN
1538-3644
DOI
10.1001/archsurg.1989.01410030138024
Publisher site
See Article on Publisher Site

Abstract

Abstract To the Editor.—Two patients from our hospital (Hartford [Conn] Hospital) who developed coagulopathies supposedly from cefotetan were recently described in the Archives.1 Having had the opportunity to evaluate these cases in detail, and having a view different from that of the author (Dr Holt), we felt obliged to write this letter. While there was a temporal relationship between cefotetan therapy and the development of hypoprothrombinemias in these patients, there were a number of other reasons for the development of coagulopathies (ie, malignant neoplasm, poor nutritional status, concurrent use of agents that effect hemostasis, and renal or hepatic dysfunction). During cefotetan therapy the nutritional status of both patients deteriorated. The first patient was without oral intake for the initial six days of her eight-day course of treatment with cefotetan and received no enteral feedings or hyperalimentation during this period. The second patient was without oral intake for the majority References 1. Holt J: Hypoprothrombinemia and bleeding diathesis associated with cefotetan therapy in surgical patients . Arch Surg 1988;123:523.Crossref 2. Mann AJ: Cimetidine associated thrombocytopenia . Drug Intell Clin Pharm 1983;17:126-128. 3. Gafter U, Komlos L, Weinstein T, et al: Thrombocytopenia, eosinophilia, and ranitidine . Ann Intern Med 1987;106:477.Crossref 4. Gibson PR, Pidcock ME: Immune- mediated thrombocytopenia associated with ranitidine therapy . Med J Aust 1986;145:661-662. 5. Spychal RT, Wickham NW: Thrombocytopenia associated with ranitidine . Br Med J 1985;291:1687.Crossref 6. Dipyridamole package insert . Ridgefield, Conn, Boehringer Ingelheim Pharmaceuticals Inc, 1985.

Journal

Archives of Surgery – American Medical Association

Published: Mar 1, 1989

There are no references for this article.